Open to opportunities

Thomas Bobinski

@thomasbobinski

Message

Experienced medicinal chemist with a focus on drug discovery.

United States

Message

What I'm looking for

I seek a role that fosters innovation and collaboration in drug development.

I am a dedicated medicinal chemist with extensive experience in drug discovery and development, particularly in optimizing synthetic methodologies and leading cross-functional teams. My work has significantly contributed to the advancement of FDA-approved therapies, including Krazati™ (adagrasib), where I led strategic development initiatives that enhanced synthesis efficiency by 500%.

Throughout my career, I have successfully managed complex projects from inception to clinical candidate nomination, utilizing advanced computational chemistry techniques and structure-based drug design. My leadership at Mirati Therapeutics and Cervello Therapeutics has resulted in accelerated target deployment and improved potency for various inhibitors, showcasing my ability to drive innovation and achieve measurable results in the pharmaceutical industry.

Experience

Work history, roles, and key accomplishments

Director, Medicinal Chemistry

Cervello Therapeutics

Nov 2019 - May 2025 (5 years 6 months)

Optimized synthesis with a team of nine FTEs, accelerating lead compound potency screening and reducing cycle time by 30% using applied organic chemistry techniques. Led cross-functional meetings biweekly to integrate SBDD approaches, achieving 5- to 10-fold acceleration in target deployment.

Potency Screening Cross Functional Team Leadership EED Inhibitors Technology Transfer

Director, Medicinal Chemistry

Cervello Therapeutics

Nov 2019 - Feb 2020 (3 months)

Streamlined PLK1 covalent inhibitor pipeline via computational chemistry techniques, reducing proprietary design timelines 10-fold. Enhanced HTRF assay sensitivity for PLK1 inhibitor evaluation, resulting in a 40% improvement in assay precision.

Computational Chemistry HTRF Assay PLK1 Inhibitors EED Inhibitors Technology Transfer Data Management

Principle Scientist

Mirati Therapeutics

Feb 2017 - Nov 2019 (2 years 9 months)

Optimized experimental techniques promoting MRTX1719's transition to an IND clinical candidate with targeted efficiency in PRMT5 inhibition. Leveraged surface plasmon resonance (SPR) screening to identify fragments with weak binding affinity for PRMT5 targets.

PRMT5 Inhibition IND Clinical Candidate SPR Screening Patent Strategy

Senior Scientist

Mirati Therapeutics

Oct 2016 - Feb 2017 (4 months)

Directed the development of synthetic methods, resulting in FDA approval of adagrasib (Krazati), demonstrating a robust impact on target-specific therapies with quantified progression metrics. Implemented advanced synthetic techniques, achieving a 10-fold increase in diversification efficiency for the 5, 6, 7, 8-Tetrahydropyrido 3, 4-d pyrimidine core.

FDA Adagrasib Process Improvement KRAS G12C Inhibitors Covalent Warheads Analytical Tools

Scientist I

Ignyta

Nov 2015 - Jun 2016 (7 months)

Structural databases were used to enhance pharmacophores with Schrödinger software, increasing the lead identification efficiency by 30% (KRAS). Optimized synthesis workflow to efficiently produce advanced intermediates and final compounds within a streamlined ten-step process, boosting compound assessment speed by 15% (KRAS).

Pharmacophores Synthesis Flow ADME Liabilities Dotmatics Suite NMR

Research Associate

Starks Associate

May 2003 - Aug 2007 (4 years 3 months)

Boosted API project outcomes, achieving a 15% cost saving by pioneering new chemistry techniques and collaborating with national research partners and leveraging NMR spectroscopy. Applied organic chemical expertise to deliver high-purity compounds that meet research standards.

NMR Compound Isolation High Purity Extraction

Education

Degrees, certifications, and relevant coursework

Purdue University

Doctor of Philosophy (Ph.D.), Chemistry, Organic Division

Grade: 3.57

Completed a Ph.D. in Chemistry with a focus on Organic Chemistry. The program involved extensive research and advanced coursework in the field.

The State University of New York at Buffalo

B.S. / M.S., Medicinal Chemistry

Grade: 3.67

Obtained both Bachelor of Science and Master of Science degrees in Medicinal Chemistry. The curriculum provided a strong foundation in drug discovery and development.